| Literature DB >> 35585582 |
Daniela Adamo1, Elena Calabria2, Federica Canfora1, Noemi Coppola1, Lorenzo Lo Muzio3, Francesca Spirito3, Michele Giuliani3, Lorenzo Azzi4, Vittorio Maurino4, Giuseppe Colella5, Chiara Colella5, Lucio Montebugnoli6, Davide Bartolomeo Gissi6, Mario Gabriele7, Marco Nisi7, Andrea Sardella8, Giovanni Lodi8, Elena Maria Varoni8, Amerigo Giudice9, Alessandro Antonelli9, Paolo Giacomo Arduino10, Alessio Gambino10, Paolo Vescovi11, Alessandra Majorana12, Elena Bardellini12, Giuseppina Campisi13, Vera Panzarella13, Francesco Spadari14, Umberto Garagiola14, Monica Pentenero15, Samuele Sutera15, Matteo Biasotto16, Giulia Ottaviani16, Margherita Gobbo16,17, Luca Guarda Nardini17, Umberto Romeo18, Gianluca Tenore18, Rosario Serpico5, Alberta Lucchese5, Carlo Lajolo19, Cosimo Rupe19, Massimo Aria20, Luca D'Aniello21, Michele Davide Mignogna1.
Abstract
BACKGROUND: Oral lichen planus (OLP) is an immune-mediated inflammatory chronic disease of the oral mucosa, with different patterns of clinical manifestations which range from keratotic manifestations (K-OLP) to predominantly non-keratotic lesions (nK-OLP). The aim of the study was to analyze the differences in the clinical, psychological profile and symptoms between Italian patients of the North and Central-South with K-OLP and nK-OLP.Entities:
Keywords: Italy; Oral lichen planus; Pain; Psychological profile; Sleep disturbances
Mesh:
Year: 2022 PMID: 35585582 PMCID: PMC9118829 DOI: 10.1186/s12903-022-02181-7
Source DB: PubMed Journal: BMC Oral Health ISSN: 1472-6831 Impact factor: 3.747
North versus Central-South differences between 270 K-OLP and 270 nK-OLP in sociodemographic profile, BMI, and risk factors
| Demographic variables | K-OLPs (N:270) | nK-OLPs (N:270) | ||||
|---|---|---|---|---|---|---|
| Nord (N:135) | Central/South (N:135) | Nord (N:135) | Central/South (N:135) | |||
| N/Frequency (%) | N/Frequency (%) | |||||
| Male | 57 (42.2) | 48 (35.6) | 0.318 | 37 (27.4) | 46 (34.1) | 0.291 |
| Female | 78 (57.8) | 87 (64.4) | 98 (72.6) | 89 (65.9) | ||
| Employed | 55 (40.7) | 50 (37) | 0.054 | 38 (28.1) | 40 (29.6) | 0.375 |
| Unemployed | 27 (20) | 44 (32.6) | 23 (17) | 31 (23) | ||
| Retired | 53 (39.3) | 41 (30.4) | 74 (54.8) | 64 (47.4) | ||
| Single | 17 (12.6) | 13 (9.6) | 0.102 | 12 (8.9) | 10 (7.4) | 0.686 |
| Married | 104 (77) | 98 (72.6) | 103 (76.3) | 98 (72.6) | ||
| Divorced | 3 (2.2) | 12 (8.9) | 7 (5.2) | 8 (5.9) | ||
| Widowed | 11 (8.1) | 12 (8.9) | 13 (9.6) | 19 (14.1) | ||
The significance difference among the percentages was measured by the Pearson Chi Square test. *Significant 0.01 < p ≤ 0.05, **Significant p ≤ 0.01
The significance difference among the percentages of family situation was measured by the Fisher’s exact test. *Significant 0.01 < p ≤ 0.05, **Significant p ≤ 0.01
K-OLP keratotic oral lichen planus, nK-OLP non-keratotic oral lichen planus
North versus Central-South differences between 270 K-OLP and 270 nK-OLP in systemic diseases and drug consumption
| K-OLPs (N:270) | nK-OLPs (N:270) | |||||
|---|---|---|---|---|---|---|
| Nord (N:135) | Central/South (N:135) | Nord (N:135) | Central/South (N:135) | |||
| N/Frequency (%) | N/Frequency (%) | |||||
| Essential hypertension | 40 (29.6) | 50 (37.9) | 0.132 | 61 (45.2) | 67 (49.6) | 0.542 |
| Hypercholesterolemia | 26 (19.3) | 32 (23.7) | 0.245 | 28 (20.07) | 35 (25.9) | 0.388 |
| Previous myocardial infarction | 2 (1.5) | 2 (1.5) | 0.459 | 3 (2.2) | 2 (1.5) | 1 |
| Diabetes mellitus type 2 | 9 (6.6) | 14 (10.3) | 0.458 | 11 (8.1) | 15 (11.1) | 0.825 |
| Asthma | 2 (1.5) | 3 (2.2) | 1 | 5 (3.7) | 9 (6.7) | 0.411 |
| Gastro-esophageal reflux disease | 17 (12.6) | 22 (16.3) | 0.489 | 36 (26.7) | 21 (15.6) | 0.036* |
| Hepatitis B | 3 (2.2) | 0 (0) | 0.247 | 0 (0) | 1 (0.7) | 1 |
| Hepatitis C | 3 (2.2) | 3 (2.2) | 1 | 4 (3.0) | 3 (2.2) | 1 |
| Endocrine disease | 4 (3.0) | 7 (5.2) | 0.54 | 5 (3.7) | 6 (4.4) | 0.411 |
| Hypothyroidism | 17 (12.6) | 17 (12.6) | 1 | 19 (14.1) | 11 (8.1) | 0.174 |
| Hyperthyroidism | 2 (1.5) | 3 (2.2) | 1 | 4 (3.0) | 3 (2.2) | 1 |
| Benign prostatic hypertrophy | 7 (5.2) | 9 (6.7) | 0.798 | 7 (5.2) | 8 (5.9) | 1 |
| Previous malignant disease | 12 (8.9) | 11 (8.1) | 1 | 12 (8.9) | 11 (8.1) | 1 |
| Beta‐Adrenergic receptor blockers | 17 (12.6) | 23 (17.0) | 0.392 | 38 (28.1) | 22 (16.3) | 0.028 |
| Angiotensin II receptor blockers | 11 (8.1) | 11 (8.1) | 1 | 12 (8.9) | 9 (6.7) | 0.65 |
| Diuretics | 7 (5.2) | 13 (9.6) | 0.245 | 5 (3.7) | 18 (13.3) | 0.008** |
| Calcium channel blockers | 6 (4.4) | 8 (5.9) | 0.785 | 14 (10.4) | 10 (7.5) | 0.522 |
| ACE-inhibitors | 10 (7.4) | 16 (11.9) | 0.302 | 24 (17.8) | 29 (21.5) | 0.54 |
| Simvastatin | 14 (10.4) | 21 (15.6) | 0.277 | 23 (17) | 30 (22.2) | 0.358 |
| Metformin | 7 (5.2) | 15 (11.1) | 0.118 | 7 (5.2) | 11 (8.1) | 0.465 |
| Insulin | 3 (2.2) | 5 (3.7) | 0.772 | 3 (2.2) | 4 (3.0) | 1 |
| Antiplatelets | 17 (12.6) | 9 (6.7) | 0.148 | 17 (12.6) | 20 (14.8) | 0.724 |
| Blood thinners | 4 (3.0) | 10 (7.4) | 0.168 | 1 (0.7) | 11 (8.1) | 0.005** |
| Levothyroxine sodium | 16 (11.9) | 20 (14.8) | 0.592 | 19 (14.1) | 13 (9.6) | 0.347 |
| Proton pump inhibitors | 14 (10.4) | 20 (14.8) | 0.359 | 26 (19.3) | 29 (21.5) | 0.763 |
The significance difference among the percentages was measured by the Fisher’s exact test. *Significant 0.01 < p ≤ 0.05, **Significant p ≤ 0.01
K-OLP keratotic oral lichen planus, nK-OLP non-keratotic oral lichen planus
North versus Central-South differences between 270 K-OLP and 270 nK-OLP in oral sites involved, and oral symptoms
| K-OLPs (N:270) | nK-OLPs (N:270) | |||||
|---|---|---|---|---|---|---|
| Nord (N:135) | Central/South (N:135) | Nord (N:135) | Central/South (N:135) | |||
| N/Frequency (%) | N/Frequency (%) | |||||
| Gingiva | 48 (35.5) | 56 (41.5) | 0.381 | 54 (40.0) | 65 (48.1) | 0.22 |
| Lips | 37 (27.4) | 40 (29.6) | 0.788 | 24 (17.8) | 38 (28.1) | 0.059 |
| Buccal mucosa | 58 (43.3) | 62 (45.9) | 0.073 | 60 (44.4) | 64 (47.4) | 0.714 |
| Tongue | 56 (41.5) | 52 (38.5) | 0.713 | 44 (32.6) | 60 (44.4) | 0.06 |
| Floor of the mouth | 35 (25.9) | 23 (17.0) | 0.709 | 13 (9.7) | 28 (20.7) | 0.017* |
| Palate | 46 (34.1) | 33 (24.4) | 0.108 | 33 (24.4) | 36 (26.7) | 0.78 |
| Retromolar trigone | 33 (24.4) | 18 (13.3) | 0.029* | 12 (8.9) | 29 (21.5) | 0.006* |
The significance difference between percentages was measured by Fisher’s exact test. *Significant 0.01 < p ≤ 0.05, **Significant p ≤ 0.01
K-OLP keratotic oral lichen planus, nK-OLP non-keratotic oral lichen planus
North versus Central-South differences between 270 K-OLP and 270 nK-OLP in pain, depression, anxiety and sleep disturbance
| K-OLPs (N:270) | nK-OLPs (N:270) | |||||
|---|---|---|---|---|---|---|
| Nord (N:135) | Central/South (N:135) | Nord (N:135) | Central/South (N:135) | |||
| Median; [IQR] | Median; [IQR] | |||||
| NRS | 0.0; [0–2.5] | 4.0; [0–6] | < 0.001** | 3.0; [0 – 6] | 5.0; [0–7] | 0.175 |
| T-PRI | 1.0; [0.2] | 3.0; [0–6] | < 0.001** | 3.0; [1–6] | 3.0; [0.5–7] | 0.427 |
| HAM-D | 5.0; [1.5–9] | 8.0; [4–14] | < 0.001** | 7.0; [4–10] | 10 [5–17] | < 0.001** |
| HAM-A | 5.0; [2–9] | 9.0; [5–12.5] | < 0.001** | 6.0; [3–12.5] | 12 [5.5–18] | 0.001** |
| PSQI | 4.0; [3–6] | 6.0; [4–8] | < 0.001** | 5.0; [3–8] | 7 [5–10] | < 0.001** |
| ESS | 4.0; [1.5–6] | 6.0; [3–9] | < 0.001** | 4.0; [2–7] | 7; [3–9.5] | 0.002** |
The significance difference among the medians was measured by the Mann–Whitney test. *Significant 0.01 < p ≤ 0.05, **Significant p ≤ 0.01
The significance difference among the percentages was measured by the Pearson Chi Square test. *Significant 0.01 < p ≤ 0.05, **Significant p ≤ 0.01
ESS Epworth sleepiness scale, K-OLP keratotic oral lichen planus, nK-OLP non-keratotic oral lichen planus, HAM-A Hamilton anxiety, HAM-D Hamilton depression, PSQI Pittsburgh sleep quality index, T-PRI Total pain rating index
Multivariate Logistic regression analysis predicting geographic area (target area Central-south = 1) in 270 K-OLP patients
| Predictors | Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beta (SE) | OR | Beta (SE) | OR | Beta (SE) | OR | Beta (SE) | OR | Beta (SE) | OR | ||||||
| Age | − 0.01 (0.02) | 0.99 | 0.612 | − 0.01 (0.02) | 0.99 | 0.659 | 0.00 (0.02) | 1.00 | 0.781 | − 0.01 (0.02) | 0.99 | 0.551 | − 0.01 (0.02) | 0.99 | 0.781 |
| Gender: female | 0.24 (0.29) | 1.27 | 0.413 | 0.01 (0.31) | 1.01 | 0.970 | 0.18 (0.30) | 1.20 | 0.543 | 0.02 (0.31) | 1.02 | 0.951 | 0.18 (0.30) | 1.20 | 0.550 |
| Years of education | 0.05 (0.04) | 1.05 | 0.225 | 0.04 (0.04) | 1.04 | 0.362 | 0.04 (0.04) | 1.04 | 0.282 | 0.05 (0.04) | 1.05 | 0.207 | 0.05 (0.04) | 1.05 | 0.192 |
| Marital status: married | − 0.27 (0.31) | 0.76 | 0.380 | − 0.37 (0.32) | 0.69 | 0.258 | − 0.18 (0.31) | 0.84 | 0.573 | − 0.30 (0.32) | 0.74 | 0.340 | − 0.27 (0.32) | 0.76 | 0.383 |
| Job: occupied | − 0.25 (0.35) | 0.78 | 0.468 | − 0.27 (0.37) | 0.76 | 0.465 | − 0.20 (0.35) | 0.82 | 0.577 | − 0.21 (0.36) | 0.81 | 0.567 | − 0.23 (0.36) | 0.80 | 0.527 |
| Smoker | − 0.07 (0.32) | 0.94 | 0.838 | 0.04 (0.34) | 1.04 | 0.900 | − 0.08 (0.32) | 0.92 | 0.801 | − 0.11 (0.33) | 0.90 | 0.747 | − 0.12 (0.33) | 0.89 | 0.712 |
| Alcohol | − 1.12 (0.31) | 0.33 | < 0.001** | − 1.00 (0.33) | 0.37 | 0.002** | − 1.17 (0.31) | 0.31 | < 0.001** | − 1.20 (0.32) | 0.30 | < 0.001** | − 0.98 (0.32) | 0.38 | 0.002** |
| BMI | 0.01 (0.03) | 1.01 | 0.821 | 0.01 (0.04) | 1.01 | 0.850 | 0.01 (0.03) | 1.01 | 0.826 | 0.00 (0.03) | 1.00 | 0.974 | 0.00 (0.03) | 1.00 | 0.882 |
| Burning | 1.02 (0.28) | 2.77 | < 0.001** | ||||||||||||
| Itching | 0.80 (0.44) | 2.23 | 0.069 | ||||||||||||
| Tingling | 0.68 (0.51) | 1.97 | 0.183 | ||||||||||||
| Retromolar Trigone | − 0.38 (0.57) | 0.68 | 0.500 | ||||||||||||
| NRS | 0.28 (0.05) | 1.33 | < 0.001** | ||||||||||||
| T-PRI | 0.23 (0.05) | 1.26 | < 0.001** | ||||||||||||
| HAM-D | |||||||||||||||
| HAM-A | |||||||||||||||
| PSQI | |||||||||||||||
| ESS | |||||||||||||||
| 5.5 | 0.015* | 11.6 | < 0.001** | 7.3 | 0.004** | 15.1 | < 0.001** | 15.2 | < 0.001** | ||||||
| 6.1 | < 0.001** | 1.8 | 0.044* | 9.6 | < 0.001** | 9.7 | < 0.001** | ||||||||
SE are the standard errors of the beta estimates. The p values were obtained from the hypothesis test on the regression coefficients. *Moderately significant .01 < p value ≤ .05. **Strongly significant p value ≤ .01
BMI body mass index, ESS Epworth sleepiness scale, HAM-A Hamilton rating scale for anxiety, HAM-D Hamilton rating scale for depression, K-OLP keratotic oral lichen planus, NRS numeric pain intensity scale, PSQI Pittsburgh quality index, T-PRI total pain rating index.,
Multivariate logistic regression analysis predicting geographic area (target area Central-south = 1) in 270 nK-OLP patients
| Predictors | Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beta (SE) | OR | Beta (SE) | OR | Beta (SE) | OR | Beta (SE) | OR | Beta (SE) | OR | ||||||
| Age | − 0.01 (0.02) | 0.99 | 0.731 | 0.00 (0.02) | 1.00 | 0.822 | − 0.01 (0.02) | 0.99 | 0.590 | 0.00 (0.02) | 1.00 | 0.842 | 0.00 (0.02) | 1.00 | 0.818 |
| Gender: Female | − 0.65 (0.28) | 0.52 | 0.018* | − 0.60 (0.29) | 0.55 | 0.041* | − 0.74 (0.29) | 0.48 | 0.011* | − 0.82 (0.29) | 0.44 | 0.005** | − 0.67 (0.29) | 0.51 | 0.020* |
| Years of education | 0.05 (0.03) | 1.06 | 0.121 | 0.07 (0.04) | 1.08 | 0.049* | 0.06 (0.04) | 1.06 | 0.101 | 0.07 (0.04) | 1.07 | 0.066 | 0.08 (0.04) | 1.08 | 0.029* |
| Marital status: married | − 0.27 (0.30) | 0.76 | 0.365 | − 0.10 (0.32) | 0.91 | 0.757 | − 0.14 (0.31) | 0.87 | 0.652 | − 0.32 (0.31) | 0.73 | 0.314 | − 0.37 (0.31) | 0.69 | 0.236 |
| Job: occupied | − 0.41 (0.41) | 0.66 | 0.314 | − 0.67 (0.43) | 0.51 | 0.122 | − 0.43 (0.42) | 0.65 | 0.307 | − 0.26 (0.42) | 0.77 | 0.537 | − 0.28 (0.42) | 0.76 | 0.509 |
| Smoker | 0.30 (0.36) | 1.35 | 0.400 | 0.27 (0.37) | 1.31 | 0.470 | 0.27 (0.37) | 1.31 | 0.464 | 0.13 (0.37) | 1.14 | 0.724 | 0.15 (0.37) | 1.16 | 0.693 |
| Alcohol | − 1.02 (0.31) | 0.36 | 0.001** | − 1.09 (0.32) | 0.34 | 0.001** | − 0.98 (0.32) | 0.38 | 0.002** | − 1.02 (0.32) | 0.36 | 0.001** | − 0.87 (0.32) | 0.42 | 0.006** |
| BMI | 0.02 (0.03) | 1.02 | 0.509 | 0.01 (0.03) | 1.01 | 0.759 | 0.03 (0.03) | 1.03 | 0.455 | 0.03 (0.03) | 1.03 | 0.374 | 0.02 (0.03) | 1.02 | 0.647 |
| Globus pharyngeus | 0.93 (0.39) | 2.52 | 0.018* | ||||||||||||
| Itching | 0.99 (0.46) | 2.69 | 0.032* | ||||||||||||
| Intraoral foreign body sensation | 1.03 (0.47) | 2.80 | 0.028* | ||||||||||||
| Floor of the mouth | 0.28 (0.47) | 1.32 | 0.554 | ||||||||||||
| Retromolar trigone | 1.02 (0.48) | 2.78 | 0.032* | ||||||||||||
| NRS | 0.10 (0.04) | 1.11 | 0.019 | ||||||||||||
| T-PRI | 0.02 (0.02) | 1.02 | 0.410 | ||||||||||||
| HAM-D | |||||||||||||||
| HAM-A | |||||||||||||||
| PSQI | |||||||||||||||
| ESS | |||||||||||||||
| 5.7 | 0.009** | 11.3 | < 0.001** | 9.0 | < 0.001** | 7.6 | 0.002** | 5.9 | 0.013* | ||||||
| 5.6 | < 0.001** | 3.3 | 0.006** | 1.9 | 0.034* | 0.2 | 0.413 | ||||||||
SE are the standard errors of the beta estimates. The p values were obtained from the hypothesis test on the regression coefficients. *Moderately significant .01 < p value ≤ .05. **Strongly significant p value ≤ .01
BMI body mass index, ESS Epworth sleepiness scale, HAM-A Hamilton rating scale for anxiety, HAM-D Hamilton rating scale for depression, nK-OLP non-keratotic oral lichen planus, NRS numeric pain intensity scale, PSQI Pittsburgh quality index, T-PRI total pain rating index